Aquestive Therapeutics, Inc. Sustainability Profile
Aquestive Therapeutics, Inc., a pioneering biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for patients with unmet medical needs. Founded in 2006, the company has made significant strides in the pharmaceutical industry, particularly in the areas of drug delivery and formulation technologies. Specialising in the development of oral films and other unique delivery systems, Aquestive's core products, such as the Suboxone Film, stand out for their ability to enhance patient compliance and improve therapeutic outcomes. With a commitment to addressing complex medical challenges, the company has established a strong market position, recognised for its advancements in the treatment of opioid dependence and other conditions. Through its dedication to innovation, Aquestive Therapeutics continues to shape the future of patient care.
DitchCarbon Score
How does Aquestive Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Aquestive Therapeutics, Inc.'s score of 23 is lower than 69% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Aquestive Therapeutics, Inc.'s reported carbon emissions
Aquestive Therapeutics, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or commitments to climate initiatives, such as those outlined by the Science Based Targets initiative (SBTi) or other industry standards. As a result, there are no significant achievements or targets to highlight regarding emissions reduction. The lack of emissions data and climate commitments suggests that Aquestive Therapeutics may still be in the early stages of developing a comprehensive sustainability strategy. In the context of the pharmaceutical industry, where climate action is increasingly critical, it will be essential for the company to consider establishing measurable targets and initiatives to address its environmental impact in the future.
How Carbon Intensive is Aquestive Therapeutics, Inc.'s Industry?
How Carbon Intensive is Aquestive Therapeutics, Inc.'s Location?
Aquestive Therapeutics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Aquestive Therapeutics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
